T0	Participants 123 202	patients treated with concomitant, quadruple, and levofloxacin-based therapies.
T1	Participants 272 306	individuals with amalgam fillings.
T2	Participants 578 663	dyspeptic patients with amalgam fillings and the effect of the amalgam fillings on H.
T3	Participants 664 707	pylori eradication rates in these patients.
T4	Participants 729 887	Four hundred and seventy-five patients who presented with dyspeptic complaints and underwent upper gastrointestinal endoscopy and gastric biopsy were included
T5	Participants 1801 1814	filling group
T6	Participants 1833 1849	nonfilling group
T7	Participants 2115 2117	H.
T8	Participants 2118 2142	pylori-positive patients
T9	Participants 2725 2755	patients with amalgam fillings
T10	Participants 2819 2849	patients with amalgam fillings